Trade Name: Glycopyrrolate

Following information is meant for : Wholesalers, Suppliers, Exporters, Doctors, CROs, Comparator Supplies, Hospitals, MOH Tender Supplies, Generic, Brand, Cooperate Sourcing, India, Institutional Buyers.

Manufacturer: Amneal Biosciences LLC

Presentation: INJECTION, HUMAN PRESCRIPTION DRUG

Strength: 0.4 mg/2mL

Storage and handling

GLYCOPYRROLATE Anticholinergic [EPC],Cholinergic Antagonists [MoA]

Disclaimer:
  1. These products are NOT FOR SALE in US territories. We offer them for Exports outside of US Territories to Trade Professionals or patients with a valid prescription.
  2. Trademark shown are property of their respective owners and GNH India does not lay any claim on them.
  3. Read more
  • No data
  • Glycopyrrolate injection, USP is a synthetic anticholinergic agent. Each 1 mL contains:
  • Glycopyrrolate, USPu00a0u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026.u2026u2026u2026.0.2 mg
  • Water for injection, USPu2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026.u2026.u2026..q.s.
  • Benzyl alcohol, NFu00a0u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026u2026.0.9% (preservative)
  • pH adjusted, when necessary, with hydrochloric acid and/or sodium hydroxide.
  • For Intramuscular (IM) or Intravenous (IV) administration.
  • Glycopyrrolate is a quaternary ammonium salt with the following chemical name: 3[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl pyrrolidinium bromide. The molecular formula is CHBrNO and the molecular weight is 398.33.
  • Its structural formula is as follows:
  • CHBrNO u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 MW 398.33
  • Glycopyrrolate, USP occurs as a white, odorless crystalline powder. It is soluble in water and alcohol, and practically insoluble in chloroform and ether.
  • Unlike atropine, glycopyrrolate is completely ionized at physiological pH values. Glycopyrrolate injection, USP is a clear, colorless, sterile liquid; pH 2.0 to 3.0. The partition coefficient of glycopyrrolate in a n-octanol/water system is 0.304 (log P= -1.52) at ambient room temperature (24u00b0C).
  • Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.
  • Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases.
  • The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily.
  • With intravenous injection, the onset of action is generally evident within one minute. Following intramuscular administration, the onset of action is noted in 15 to 30 minutes, with peak effects occurring within approximately 30 to 45 minutes. The vagal blocking effects persist for 2 to 3 hours and the antisialagogue effects persist up to 7 hours, periods longer than for atropine.
  • The following pharmacokinetic information and conclusions were obtained from published studies that used nonspecific assay methods.
  • In Anesthesia
  • Glycopyrrolate injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants.
  • In Peptic Ulcer
  • For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.
  • Known hypersensitivity to glycopyrrolate injection or any of its inactive ingredients.
  • In addition, in the management of patients, because of the longer duration of therapy, Glycopyrrolate injection may be contraindicated in patients with the following concurrent conditions: glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.
  • This drug should be used with great caution, if at all, in patients with glaucoma.
  • Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources (see ).
  • Glycopyrrolate injection may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.
  • In addition, in the presence of fever, high environmental temperature and/or during physical exercise, heat prostration can occur with use of anticholinergic agents including glycopyrrolate (due to decreased sweating), particularly in children and the elderly.
  • Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with glycopyrrolate injection would be inappropriate and possibly harmful.
  • No data
  • Anticholinergics, including glycopyrrolate injection, can produce certain effects, most of which are extensions of their pharmacologic actions. Adverse reactions may include xerostomia (dry mouth); urinary hesitancy and retention; blurred vision and photophobia due to mydriasis (dilation of the pupil); cycloplegia; increased ocular tension; tachycardia; palpitation; decreased sweating; loss of taste; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; severe allergic reactions including anaphylactic/anaphylactoid reactions; hypersensitivity; urticaria, pruritus, dry skin, and other dermal manifestations; some degree of mental confusion and/or excitement, especially in elderly persons.
  • In addition, the following adverse events have been reported from post-marketing experience with glycopyrrolate: malignant hyperthermia; cardiac arrhythmias (including bradycardia, ventricular tachycardia, ventricular fibrillation); cardiac arrest; hypertension; hypotension; seizures; and respiratory arrest. Post-marketing reports have included cases of heart block and QTc interval prolongation associated with the combined use of glycopyrrolate and an anticholinesterase. Injection site reactions including pruritus, edema, erythema, and pain have also been reported.
  • Glycopyrrolate is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the blood-brain barrier is limited in contrast to atropine sulfate and scopolamine hydrobromide. For this reason the occurrence of CNS-related side effects is lower, in comparison to their incidence following administration of anticholinergics which are chemically tertiary amines that can cross this barrier readily.
  • To report SUSPECTED ADVERSE REACTIONS, contact Amnealu00a0Pharmaceuticalsu00a0at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • To combat peripheral anticholinergic effects, a quaternary ammonium anticholinesterase such as neostigmine methylsulfate (which does not cross the blood-brain barrier) may be given intravenously in increments of 0.25 mg in adults. This dosage may be repeated every five to ten minutes until anticholinergic overactivity is reversed or up to a maximum of 2.5 mg. Proportionately smaller doses should be used in pediatric patients. Indication for repetitive doses of neostigmine should be based on close monitoring of the decrease in heart rate and the return of bowel sounds.
  • If CNS symptoms (e.g., excitement, restlessness, convulsions, psychotic behavior) occur, physostigmine (which does cross the bloodu2013brain barrier) may be used. Physostigmine 0.5 to 2 mg should be slowly administered intravenously and repeated as necessary up to a total of 5 mg in adults. Proportionately smaller doses should be used in pediatric patients.
  • To combat hypotension, administer IV (Intravenous) fluids and/or pressor agents along with supportive care.
  • Fever should be treated symptomatically.
  • Following overdosage, a curare-like action may occur, i.e. neuromuscular blockade leading to muscular weakness and possible paralysis. In the event of a curare-like effect on respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns.
  • NOTE: CONTAINS BENZYL ALCOHOL n- Array
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
  • Glycopyrrolate injection may be administered intramuscularly, or intravenously, without dilution, in the following indications.
  • Adults
  • PREANESTHETIC MEDICATION
  • The recommended dose of glycopyrrolate injection is 0.004 mg/kg by intramuscular injection, given 30 to 60 minutes prior to the anticipated time of induction of anesthesia or at the time the preanesthetic narcotic and/or sedative are administered.
  • INTRAOPERATIVE MEDICATION
  • Glycopyrrolate injection may be used during surgery to counteract drug-induced or vagal reflexes and their associated arrhythmias (e.g., bradycardia). It should be administered intravenously as single-doses of 0.1 mg and repeated, as needed, at intervals of 2 to 3 minutes. The usual attempts should be made to determine the etiology of the arrhythmia, and the surgical or anesthetic manipulations necessary to correct parasympathetic imbalance should be performed.
  • REVERSAL OF NEUROMUSCULAR BLOCKADE
  • The recommended dose of glycopyrrolate injection is 0.2 mg for each 1 mg of neostigmine or 5 mg of pyridostigmine. In order to minimize the appearance of cardiac side effects, the drugs may be administered simultaneously by intravenous injection and may be mixed in the same syringe.
  • PEPTIC ULCER
  • The usual recommended dose of glycopyrrolate injection is 0.1 mg administered at 4-hour intervals, 3 or 4 times daily intravenously or intramuscularly. Where more profound effect is required, 0.2 mg may be given. Some patients may need only a single-dose, and frequency of administration should be dictated by patient response up to a maximum of four times daily.
  • Glycopyrrolate injection is not recommended for the treatment of peptic ulcer in pediatric patients (seen ).
  • Pediatric Patients
  • (see )
  • PREANESTHETIC MEDICATION
  • The recommended dose of glycopyrrolate injection in pediatric patients is 0.004 mg/kg intramuscularly, given 30 to 60 minutes prior to the anticipated time of induction of anesthesia or at the time the preanesthetic narcotic and/or sedative are administered.
  • INFANTS
  • (1 month to 2 years of age) may require up to 0.009 mg/kg.
  • INTRAOPERATIVE MEDICATION
  • Because of the long duration of action of glycopyrrolate injection if used as preanesthetic medication, additional glycopyrrolate injection for anticholinergic effect intraoperatively is rarely needed; in the event it is required the recommended pediatric dose is 0.004 mg/kg intravenously, not to exceed 0.1 mg in a single-dose which may be repeated, as needed, at intervals of 2 to 3 minutes. The usual attempts should be made to determine the etiology of the arrhythmia, and the surgical or anesthetic manipulations necessary to correct parasympathetic imbalance should be performed.
  • REVERSAL OF NEUROMUSCULAR BLOCKADE
  • The recommended pediatric dose of glycopyrrolate injection is 0.2 mg for each 1 mg of neostigmine or 5 mg of pyridostigmine. In order to minimize the appearance of cardiac side effects, the drugs may be administered simultaneously by intravenous injection and may be mixed in the same syringe.
  • PEPTIC ULCER
  • Glycopyrrolate injection is not recommended for the treatment of peptic ulcer in pediatric patients (see ).
  • Diluent Compatibilities
  • Dextrose 5% and 10% in water, or saline, dextrose 5% in sodium chloride 0.45%, sodium chloride 0.9%, and Ringeru2019s Injection.
  • Diluent Incompatibilities
  • Lactated Ringeru2019s solution
  • Admixture Compatibilities
  • PHYSICAL COMPATIBILITY
  • This list does not constitute an endorsement of the clinical utility or safety of co-administration of glycopyrrolate injection with these drugs. Glycopyrrolate injection is compatible for mixing and injection with the following injectable dosage forms: atropine sulfate, USP; Antilirium(physostigmine salicylate); Benadryl (diphenhydramine HCl); codeine phosphate, USP; Emete-Con(benz-quinamide HCl); hydromorphone HCl, USP; Inapsine (droperidol); Levo-Dromoran(levorphanol tartrate); lidocaine, USP; meperidine HCl, USP; Mestinon/Regonol (pyridostigmine bromide); morphine sulfate, USP; Nubain (nalbuphine HCl); Numorphan (oxymorphone HCl); procaine HCl, USP; promethazine HCl, USP; Prostigmin (neostigmine methylsulfate, USP); scopolamine HBr, USP; Stadol (butorphanol tartrate); Sublimaze (fentanyl citrate); Tigan(trimethobenzamide HCl); and Vistaril (hydroxyzine HCl). Glycopyrrolate injection may be administered via the tubing of a running infusion of normal saline.
  • Admixture Incompatibilities
  • PHYSICAL INCOMPATIBILITY
  • Since the stability of glycopyrrolate is questionable above a pH of 6.0 do not combine glycopyrrolate injection in the same syringe with Brevital (methohexital Na); Chloromycetin(chloramphenicol Na succinate); Dramamine (dimenhydrinate); Nembutal (pentobarbital Na); Pentothal (thiopental Na); Seconal (secobarbital Na); sodium bicarbonate (Abbott); Valium(diazepam); Decadron (dexamethasone Na phosphate); or Talwin (pentazocine lactate). These mixtures will result in a pH higher than 6.0 and may result in gas production or precipitation.
  • Glycopyrrolate injection USP, , is supplied as single and multiple-dose vials available in following strengths and package sizes:
  • 0.2 mg/mL, 1 mL vial
  • Single-dose vial: u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 NDC 70121-1394-1
  • 25 single-dose vials in a carton: u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a0 NDC 70121-1394-5
  • 0.2 mg/mL, 2 mL vial
  • Single-dose vial: u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 NDC 70121-1395-1
  • 25 single-dose vials in a carton: u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a0u00a0 NDC 70121-1395-5
  • 0.2 mg/mL, 5 mL vial
  • Multiple-dose vial: u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 NDC 70121-1396-1
  • 25 multiple-dose vials in a carton: u00a0u00a0u00a0 u00a0u00a0 u00a0 NDC 70121-1396-5
  • 0.2 mg/mL, 20 mL vial
  • Multiple-dose vial: u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 NDC 70121-1397-1
  • 10 multiple-dose vials in a carton: u00a0 u00a0 u00a0u00a0 u00a0 NDC 70121-1397-7n n
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F) [see USP Controlled Room Temperature].
  • All trademarks are the property of their respective owner.
  • Discard unused portion of single-dose vials.n
  • Manufactured by:n Ahmedabad 382213, INDIA
  • Distributed by:n Bridgewater, NJ 08807
  • Rev. 01-2020-02
  • Arrayn- Array
  • u00a0
  • u00a0
  • u00a0
  • u00a0
  • u00a0
  • u00a0
  • u00a0
  • Arrayn- Array
  • u00a0
  • u00a0

Ask for Quote

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler, Supplier, Exporters from India of Glycopyrrolate (Glycopyrrolate) which is also known as Glycopyrrolate and Manufactured by Amneal Biosciences LLC. It is available in strength of 0.4 mg/2mL.

Glycopyrrolate (Glycopyrrolate) is supplied for Tenders, Emergency imports, Un - licensed, Specials, Orphan drug, Name patient line, RLD supplies, Reference listed drugs, Comparator Drug, Bio-Similar, Innovator samples, For Clinical trials. Click to know price.

Browse Our Services And Processes

Name Patient Supply

Name Patient Supply

Validated Cold Chain Shipment

Validated Cold Chain Shipment

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

Our Process - The Gnh Way

Our Process - The Gnh Way

Other Pharmaceutical Products

desogestrel and ethinyl estradiol (EMOQUETTE)

desogestrel and ethinyl estradiol (EMOQUETTE)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Melphalan Injection IP 50mg (Alkacel)

Melphalan Injection IP 50mg (Alkacel)

Monobenzone Cream USP 20% (Albaquin)

Monobenzone Cream USP 20% (Albaquin)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Are you an existing customer or a vendor of GNH India? Log in here to